$0.61
5.96% today
Nasdaq, Feb 28, 05:17 pm CET
ISIN
US47010C3007
Symbol
JAGX
Sector
Industry

Jaguar Health, Inc. Stock price

$0.58
-0.31 35.31% 1M
-0.59 50.79% 6M
-0.43 43.00% YTD
-2.90 83.43% 1Y
-2,049.17 99.97% 3Y
-8,033.27 99.99% 5Y
-96,106,499.42 100.00% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.11 15.59%
ISIN
US47010C3007
Symbol
JAGX
Sector
Industry

Key metrics

Market capitalization $9.39m
Enterprise Value $32.37m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 3.09
P/S ratio (TTM) P/S ratio 0.90
P/B ratio (TTM) P/B ratio 0.44
Revenue growth (TTM) Revenue growth -2.25%
Revenue (TTM) Revenue $10.48m
EBIT (operating result TTM) EBIT $-29.86m
Cash position $13.27m
EPS (TTM) EPS $-16.10
P/E forward negative
P/S forward 0.83
EV/Sales forward 2.86
Short interest 6.00%
Show more

Is Jaguar Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Jaguar Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Jaguar Health, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Jaguar Health, Inc.:

Buy
100%

Financial data from Jaguar Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
10 10
2% 2%
100%
- Direct Costs 4.44 4.44
22% 22%
42%
6.04 6.04
15% 15%
58%
- Selling and Administrative Expenses 18 18
1% 1%
172%
- Research and Development Expense 15 15
20% 20%
148%
-28 -28
10% 10%
-262%
- Depreciation and Amortization 2.36 2.36
2% 2%
23%
EBIT (Operating Income) EBIT -30 -30
10% 10%
-285%
Net Profit -38 -38
5% 5%
-360%

In millions USD.

Don't miss a Thing! We will send you all news about Jaguar Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Jaguar Health, Inc. Stock News

Neutral
Accesswire
one day ago
Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease FDA meeting expected in Q2 2025 on the statistically significant results of the Phase 3 OnTarget trial of crofelemer in the prespecified subgroup of patients with breast cancer Jaguar has rece...
Neutral
Accesswire
9 days ago
This study, initiated yesterday, is one of five clinical efforts - three proof-of-concept (POC) investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications of SBS-IF and microvillus inclusion disease (MVID) in the US, EU, and/or Middle East/North Africa regions Availability of first IIT proof-of-concept results potentially in H1 2025 Crofelemer, ...
Neutral
Accesswire
10 days ago
Priority Review Vouchers (PRVs) are transferable and, in past transactions by other companies, have sold for prices up to $350 million 1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related deaths occur each year worldwide SAN FRANCISCO, CA / ACCESS Newswire / February 18, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") and Jaguar family company Napo Pharmaceu...
More Jaguar Health, Inc. News

Company Profile

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Head office United States
CEO Lisa Conte
Employees 49
Founded 2013
Website www.jaguar.health

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today